Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
72.98
+0.93 (1.29%)
At close: Apr 3, 2025, 4:00 PM
72.28
-0.70 (-0.96%)
Pre-market: Apr 4, 2025, 4:21 AM EDT

Company Description

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.

The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands.

It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.

The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Edwards Lifesciences Corporation
Edwards Lifesciences logo
Country United States
Founded 1958
IPO Date Mar 27, 2000
Industry Medical Devices
Sector Healthcare
Employees 15,800
CEO Bernard Zovighian

Contact Details

Address:
One Edwards Way
Irvine, California 92614
United States
Phone 949 250 2500
Website edwards.com

Stock Details

Ticker Symbol EW
Exchange NYSE
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001099800
CUSIP Number 28176E108
ISIN Number US28176E1082
Employer ID 36-4316614
SIC Code 3842

Key Executives

Name Position
Bernard J. Zovighian Chief Executive Officer and Director
Scott B. Ullem Corporate Vice President and Chief Financial Officer
Donald E. Bobo Jr. Corporate Vice President of Strategy and Corporate Development
Larry L. Wood Corporate Vice President and Group President of TAVR and Surgical Structural Heart
Andrew M. Dahl Principal Accounting Officer, Senior Vice President and Corporate Controller
Dr. Todd J. Brinton FACC, M.D. Corporate Vice President of Advanced Technology and Chief Scientific Officer
Mark Wilterding Vice President of Investor Relations
Arnold A. Pinkston J.D. Corporate Vice President and General Counsel
Dirksen J. Lehman Corporate Vice President of Public Affairs
Christine Z. McCauley Corporate Vice President of Human Resources

Latest SEC Filings

Date Type Title
Mar 26, 2025 ARS Filing
Mar 26, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 26, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 26, 2025 DEF 14A Other definitive proxy statements
Mar 26, 2025 144 Filing
Mar 10, 2025 144 Filing
Mar 10, 2025 144 Filing
Feb 28, 2025 10-K Annual Report
Feb 14, 2025 144 Filing
Feb 13, 2025 144 Filing